Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07598890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Clinical Trial of Adsorbed Tetanus Vaccine

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 21, 2026 to Jun 20, 2026
    • Study completion moved earlier from Mar 21, 2027 to Dec 31, 2026
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 1 of 7 entries
  2. Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Site contact updated
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, parallel-controlled Phase I clinical trial of Adsorbed Tetanus Vaccine. Participants aged ≥18 years will receive one dose of the vaccine to evaluate its safety and immunogenicity.
Trial Details
NCT Number NCT07598890
Lead Sponsor Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Conditions
(from sponsor)		 Tetanus
Related terms Tetanus
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov